FDA approves EMD Serono-Pfizer's Rebif auto-injector

Rebif Rebidose eases MS treatment compliance
Tools

The FDA has approved Rebif Rebidose, a single-use auto-injector prefilled with EMD Serono and Pfizer's ($PFE) interferon beta-1a, for the treatment of relapsing forms of multiple sclerosis. Interferon beta-1a is an established and effective disease-modifying treatment for MS, but some people can struggle with injections, and the resulting drops in compliance mean the treatment is less effective. A simple-to-use, single-use auto-injector as an alternative delivery option could make it easier for patients to self-administer the drug. Rebif Rebidose's approval follows a 12-week Phase IIIb multicenter, open-label, single-arm study, wherein most of the patients found the Rebif Rebidose device easy to use. EMD Serono is the U.S. subsidiary of Merck KGaA of Darmstadt, Germany. Press release